BiotechTube

V503 + Gardasil

Phase 3Active
0 views this week 0 watching⚡ Active
Interest: 44/100
44
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Papillomavirus Infections

Conditions

Papillomavirus Infections

Trial Timeline

Jun 26, 2019 → Mar 31, 2028

NCT ID
NCT03998254

About V503 + Gardasil

V503 + Gardasil is a phase 3 stage product being developed by Merck for Papillomavirus Infections. The current trial status is active. This product is registered under clinical trial identifier NCT03998254. Target conditions include Papillomavirus Infections.

What happened to similar drugs?

2 of 20 similar drugs in Papillomavirus Infections were approved

Approved (2) Terminated (0) Active (18)
🔄9vHPV vaccineMerckPhase 3
✅Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
🔄V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
🔄V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
✅GardasilMerckApproved
🔄9vHPV VaccineMerckPhase 3
🔄9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT03998254Phase 3Active
NCT02653118Pre-clinicalActive
NCT02114385Phase 3Completed
NCT01304498Phase 3Completed

Competing Products

20 competing products in Papillomavirus Infections

See all competitors
ProductCompanyStageHype Score
AAVLP-HPV + Placebo2A PharmaPhase 1
19
9vHPV vaccineMerckPhase 3
44
Human Papillomavirus 9-valent Vaccine, RecombinantMerckApproved
43
V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)MerckPhase 3
40
V503 + Comparator: Menactra™ (Concomitant) + Comparator: Adacel™ (Concomitant) + Comparator: Menactra™ (Non-Concomitant) + Comparator: Adacel™ (Non-concomitant)MerckPhase 3
40
Quadrivalent human papillomavirus vaccine on-time administration + Quadrivalent human papillomavirus vaccine delayed administrationMerckPre-clinical
26
GardasilMerckApproved
43
GardasilMerckPhase 2
35
9vHPV VaccineMerckPhase 3
44
9vHPV Vaccine + mRNA-1273 VaccineMerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant VaccineMerckPhase 3
40
V503 + GARDASILMerckPhase 3
40
9vHPV VaccineMerckPhase 3
44
Gardasil vaccineMerckPre-clinical
26
V503MerckPhase 3
40
Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™) + PlaceboMerckPhase 3
40
V503 Vaccine + REPEVAX™ (Concomitant) + REPEVAX™ (Non-concomitant)MerckPhase 3
40
9vHPV vaccineMerckPhase 3
40
Gardasil™ + PlaceboMerckPhase 3
40
9vHPV vaccineMerckPhase 3
40